We demonstrated that PP2A regulatory subunit PPP2R2B is a major subunit of PP2A whose downregulation is associated with poor prognosis in HER2+ breast cancer and resistance to anti-HER2 treatments, including both HER2-targeting antibody trastuzumab and HER2 kinase inhibitor lapatinib. This evidence concerns the gene PTPA and breast carcinoma.